🎉✨ We are thrilled to celebrate reaching 1,000 subscribers on our Telegram channel dedicated to the professional development of medical laboratory scientists! This milestone is not just a number; it represents a vibrant community of passionate individuals united by a shared commitment to advancing our understanding of science and its profound impact on healthcare. Your support and engagement have been instrumental in fostering an environment where big ideas flourish, and we encourage each of you to continue sharing this channel with your peers and colleagues. Together, we can inspire the next generation of medical professionals and elevate our collective knowledge. Let’s keep the momentum going—every new subscriber enhances our discussions, broadens our perspectives, and enriches our community. Thank you for being part of this journey; your enthusiasm fuels our mission to empower and educate! Here’s to many more milestones together as we explore the fascinating world of medical laboratory science! 🌟🔬
👇👇👇👇👇👇👇👇
https://t.me/Laboratorypractice

Test : Leukocyte Cytochemistry/ Cytochemistry, Leukocyte

Indications : Test evaluate neoplasm and abnormal cells in bone marrow, peripheral blood, or other specimens such as imprints, detect amylodois, classify leukemias and plasma cell dyscrasias, and evaluate myeloproliferative disorders.
Interpretation : For each type of leukemic blast a consistent and distinctive pattern of non specific esterases activity has been reported. Isoenzyme fractions of acid phosphatases and nonspecific esterases appear to be unique for lymphoblasts, myeloblasts, and immature or leukemic monocytes.
Related Tests : Leukocyte Alkaline Phosphatase, Muramidase, Peripheral blood differential leukocyte count, Tartarate resistant Leukocyte Acid phosphatase, White Blood count.
👇👇👇👇👇👇👇👇👇👇👇👇
https://t.me/Laboratorypractice

Vacancy Announcement |

Organization: Adera Medical Center
Location: Addis Ababa
Employment: Full-Time

Open Positions:

General Surgeon: Specialist with 5+ years experience (2)

Internist: Specialist with 5+ years experience (5)

Obstetrician/Gynecologist: Specialist with 3+ years experience (2)

Pediatrician: Specialist with 3+ years experience (2)

General Practitioner: Degree, 0+ years experience (10)

Manager: MSc/BSc in Management/Health, 5+ years experience (1)

Head of Laboratory: BSc/MSc with 5+ years leadership experience

Pharmacy Department Head: BSc with 6+ years leadership experience

Import Technical Manager: BSc in Pharmacy with 3+ years experience

Senior Pharmacist: BSc with 4+ years experience (5)

Junior Pharmacist: Diploma/BSc with 1+ year experience (5)

Druggist: Diploma with 2+ years experience (3)

Oncology Nurse: BSc/Diploma with experience (5)

Pediatric ICU Nurse: BSc with 2+ years experience (10)

Adult ICU Nurse: BSc/Diploma with 2+ years ICU experience (5)

OR Nurse: Diploma/BSc with 2+ years experience (10)

Emergency Dept. Nurse: Diploma/BSc with 2+ years experience (10)

Clinical Nurse: Diploma/BSc with 2+ years experience (20)

Midwife: BSc/Diploma with 5+ years experience (10)

Senior Lab Technologist: BSc with 2+ years experience (10)

Lab Technician / Phlebotomist: Diploma with 2+ years experience (15)

Pathology Technologist: BSc with experience (3)

Radiology Technologist: BSc with 2+ years experience (5)

Anesthesia Professional: MSc/BSc with 2+ years experience (5)

Environmental Health Professional: BSc with 2+ years experience (5)

Important Notes:

• All health professionals must have a renewed professional license.
• Experience in a private healthcare facility is preferred.

How to Apply:

Deadline: July 30, 2025

Submit your application in person at the center's Human Resources Department or via email to aderamedicalcenter2023@gmail.com.
https://t.me/Laboratorypractice

A blood test breast cancer




They found a promising-looking signature in the women’s white blood cells that was linked to their chance of developing cancer. But what about women who didn’t carry a faulty BRCA1 gene?
When they looked at larger studies for this signature in women who didn’t carry a BRCA1 fault, they found that the signature appeared in the blood of women who went on to develop the disease.
This strongly suggests there’s something in these women’s blood that could be used to help work out their chance of breast cancer in later life. But – crucially – it also throws up several questions:
What is this a signature of?
Why is it in white blood cells?
How long before breast cancer develops does it appear?
Why does it appear?
Is it an early sign of a cancer itself, or of an underlying process that precedes the disease?
How is it affected by other things that affect breast cancer risk, like bodyweight and age?
All of these questions – and more – need to be answered before we can start talking about ‘tests’ available on the NHS.
A simple blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, even in the absence of a high-risk BRCA1 gene mutation, according to research published in the open access journal Genome Medicine.
Researchers from UCL identified an epigenetic signature in the blood of women predisposed for breast cancer owing to an inherited genetic mutation of the BRCA1 gene. Epigenetic alterations are thought to be key molecular switches that are involved in the development of cancer. Strikingly, the same signature was discovered in the blood of women without a BRCA1 mutation but who went on to develop breast cancer, making it a potential early marker of women’s cancer in the general population.
BRCA1 mutation is inherited from a parent, and is the cause of at least ten percent of breast cancers. The cause of the remaining 90% of sporadic breast cancers in non-mutation carriers remains to be explained. Scientists are beginning to understand that genetic mutations are not the sole contributors to disease development and that the way in which genes are arranged in our cells can affect whether they function appropriately – that is, whether they are turned on or off. The arrangement and expression of our genes is overseen by the process of epigenetics. One of the most studied epigenetic mechanisms is a process called DNA methylation, which was the focus of the current study.
In this study, researchers used blood samples collected several years before breast cancer development from two large UK cohorts of women – the MRC National Survey of Health and Development and the UK Collaborative Trial of Ovarian Cancer Screening. They looked at the DNA methylation signature from blood of those women with and without BRCA1 mutations. When this signature was applied to samples from both these groups, those women who developed non-hereditary cancers were found to have the same DNA methylation signature.
Professor Martin Widschwendter, the study’s lead author and Head of University College London’s Department of Women’s Cancer says: “We identified an epigenetic signature in women with a mutated BRCA1 gene that was linked to increased cancer risk and lower survival rates. Surprisingly, we found the same signature in large cohorts of women without the BRCA1 mutation and it was able to predict breast cancer risk several years before diagnosis.”
Share this link
👇👇👇👇👇👇👇
@Laboratorypractice